Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multiple sclerosis vaccine - Aixlie

Drug Profile

Multiple sclerosis vaccine - Aixlie

Latest Information Update: 22 May 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ohio State University
  • Developer Aixlie Pharmaceuticals; Ohio State University
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 22 May 2002 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
  • 08 Feb 2001 New profile
  • 08 Feb 2001 The vaccine is available for licensing (http://hometown.aol.com/aixlie/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top